Germline mutations in BRCA genes have been associated with pancreatic cancer. Laboratory and clinical data suggest thatpatients with BRCA mutations may be more responsive to therapy consisting of conventional chemotherapy with apoly(ADP-ribose) polymerase inhibitor (PARPi). The most recent data from the 2013 American Society of Clinical Oncology(ASCO) Annual Meeting will be reviewed (Abstracts #11024 and #TPS4144).
Muhammad Wasif Saif, Gregory T Brennan, Valerie Relias
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : September 22, 2019